August 1, 2024 08:56 AM EDT
Deals
Pharma

Ab­b­Vie clos­es $8.7B Cerev­el deal in bid to com­pete with Bris­tol My­ers in schiz­o­phre­nia

Kyle LaHucik

Senior Reporter

Ab­b­Vie has re­ceived reg­u­la­to­ry clear­ance to com­plete its $8.7 bil­lion ac­qui­si­tion of neu­ro­science biotech Cerev­el Ther­a­peu­tics, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

WuXi AppTec is still sign­ing on new clients de­spite Biose­cure threat

BeiGene ex­ec­u­tive re­port­ed­ly un­der in­ves­ti­ga­tion in Chi­na

For­mer Seagen CEO David Ep­stein to lead new biotech with VEGF bi­func­tion­al an­ti­body

No­var­tis pays Monte Rosa $150M for Phase 1 drug in lat­est en­dorse­ment of mol­e­c­u­lar glues

Await­ing ex­pand­ed ap­provals, Lil­ly and J&J re­lease late-stage da­ta for Crohn's treat­ments

A service from the Financial Times